Related references
Note: Only part of the references are listed.Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz et al.
BLOOD (2020)
Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends
Mohamed M. Gad et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Molecular Pathogenesis of Cholangiocarcinoma
Peter L. Labib et al.
BMC CANCER (2019)
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study
Justin M. Watts et al.
BLOOD (2019)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Thinking beyond Opisthorchis viverrini for risk of cholangiocarcinoma in the lower Mekong region: a systematic review and meta-analysis
Jennifer A. Steele et al.
INFECTIOUS DISEASES OF POVERTY (2018)
Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours
Remco J. Molenaar et al.
BMJ OPEN (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar et al.
CELL REPORTS (2017)
Intrahepatic, Perihilar and Distal Cholangiocarcinoma: Management and Outcomes
David Waseem et al.
ANNALS OF HEPATOLOGY (2017)
IDH mutations in cancer and progress toward development of targeted therapeutics
L. Dang et al.
ANNALS OF ONCOLOGY (2016)
Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma
Nestor F. Esnaola et al.
CANCER (2016)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Darrell R. Borger et al.
CLINICAL CANCER RESEARCH (2014)
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Sumera Rizvi et al.
GASTROENTEROLOGY (2013)
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Daniela Sia et al.
GASTROENTEROLOGY (2013)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
D. Sia et al.
ONCOGENE (2013)
Exome sequencing of liver fluke-associated cholangiocarcinoma
Choon Kiat Ong et al.
NATURE GENETICS (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations
Genglin Jin et al.
PLOS ONE (2011)
The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
Fonnet E. Bleeker et al.
ACTA NEUROPATHOLOGICA (2010)
IDH1 and IDH2: Not Your Typical Oncogenes
Zachary J. Reitman et al.
CANCER CELL (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution
Michelle L. DeOliveira et al.
ANNALS OF SURGERY (2007)
p53 mutations in human cholangiocarcinoma: a review
SA Khan et al.
LIVER INTERNATIONAL (2005)
Share Paper
